What Is MK-2866 50MG / ML | 60ML?
MK-2866 is also known by the names of ostarine and GTx-024. It belongs to the class selective androgen receptor modulator (SARM). It was initially developed by a pharmaceutical company, GTx. Inc, for conditions like muscle wasting and osteoporosis. Research shows that it increases muscle mass and growth, improves insulin sensitivity and prevents bone loss. It has also been shown to treat breast cancer. The research on ostarine is limited and it is classified as an investigational drug. Furthermore, it is banned by the World Anti-Doping Agency (WADA) as it has been shown to increase strength performance. At Pinnacle Peptides, MK-2866 for sale is exclusively available for research and experimentation.
Structure Of MK-2866 50MG / ML | 60ML
IUPAC Name: (2S)-3-(4-cyanophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide
Synonyms: ENOBOSARM, Ostarine, 841205-47-8, GTx-024
Molecular Formula: C19H14F3N3O3
Molecular Weight: 389.3 g/mol
CAS number: 841205-47-8
PubChem CID: 11326715
Mechanism Of MK-2866 50MG / ML | 60ML
Mk-2866 is an androgen receptor modulator that has been shown to only exert anabolic effects without targeting receptors in prostate tissues. It binds with androgen receptors in specific tissues such as muscles. This triggers the cascade of intracellular signaling, resulting in protein synthesis within muscle cells that promotes muscle growth and repair. Furthermore, ostarine has been shown to influence bone cells.
1. Stress Urinary Incontinence
Stress urinary incontinence is characterized by the involuntary leakage of urine due to weakened pelvic floor muscles. It has been shown that androgen receptors are abundantly present in the pelvic floor, and the drugs that modulate these receptors might prove useful for the treatment of stress urinary incontinence. Research on the ovariectomized mouse model found that Mk-2866 increased the pelvic floor muscle mass, which might translate into improved symptoms of urinary incontinence . However, the drug couldn’t pass the phase II clinical trial conducted on postmenopausal women as it didn’t meet the primary endpoint .
2. Muscle Mass
Research suggests that muscle mass and physical function decline with advancing age due to hormonal changes in postmenopausal women. As a SARM, Mk-2866 might be able to restore or at least prevent a decrease in muscle function. In an ovariectomized rat study, a five-week ostarine treatment resulted in increased capillary density in the gastrocnemius and longissimus muscles compared to untreated rats, indicating improved health of muscle tissue .
Similarly, a study was conducted to explore the effects of ostarine on postmenopausal women and elderly men. Participants were randomly assigned to receive 0.1, 0.3, 1 mg, 3 mg ostarine, or a placebo for three months. The results demonstrated that Mk-2866 increases mass in a dose-dependent manner as it was found to enhance the body mass, with a 1.4 kg increase at a 3 mg dose compared to the placebo. Additionally, the patients who were treated with the drug exhibited improvements in the stair climbing test, reflecting improved physical performance in terms of both speed and power .
Cachexia is characterized by loss of skeletal muscles and strength. One study investigated the effect of ostarine on cachexia in cancer patients. Non-obese postmenopausal women and men, who lost 2% weight during cancer treatment, were enrolled in the study. The subjects were randomly administered either ostarine (1mg, 3mg) or a placebo for 113 days. The results indicated a significant increase in lean body mass in patients who took ostarine as compared to the control group .
3. Insulin Sensitivity
Results from a phase II trial conducted on postmenopausal women and elderly men found that 3mg enobosarm reduced fasting blood glucose (FBG) levels by 11% and insulin resistance by 26.8%. The antidiabetic effect of MK-2866 was more significant in prediabetic women who experienced a reduction in FBG by 17% and insulin resistance by 43% .
4. Bone Mineral Density
One study in a rat model of osteoporosis found that Mk-2866 treatment for 35 days resulted in increased bone mineral density and bone volume density . Similarly, another study replicated similar results in ovariectomized rats. It found that ostarine treatment resulted in enhanced callus formation and increased callus density, initiating the process of bone healing .
5. Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer
Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer (AR+ TNBC) is linked with the overexpression of androgen receptors. Hence, drugs that target this receptor might show effectiveness for breast cancer treatment. Research shows that a combination of MK-2866 and pembrolizumab can improve clinical response by 25% with tolerable side effects .
MK-2866 is a selective androgen receptor modulator. It selectively targets androgen receptors in specific tissues and exhibits anabolic function. It has been shown to increase muscle mass, improve insulin sensitivity and treat AR+ TNMC. It is an investigation drug that has not been approved by the FDA yet. We don’t support its unwarranted use and offer MK-2866 for research and educational institutions. Only Mk-2866 if you are a qualified researcher.
- Ponnusamy, S., et al., Tissue Selective Androgen Receptor Modulators (SARMs) Increase Pelvic Floor Muscle Mass in Ovariectomized Mice. J Cell Biochem, 2017. 118(3): p. 640-646.
- Writer, G. S. (2023, June 2). GTx’s Enobosarm Fails Phase II Trial in Stress Urinary Incontinence; Stock Plunges 90%+. GEN - Genetic Engineering and Biotechnology News.
- Roch, P.J., et al., Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model. Frontiers in Endocrinology, 2020. 11.
- Evans, W., et al., Ostarine increases lean body mass and improves physical performance in healthy elderly subjects: Implications for cancer cachexia patients. Journal of Clinical Oncology, 2007. 25(18_suppl): p. 9119-9119.
- Dobs, A.S., et al., Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomized controlled phase 2 trial. Lancet Oncol, 2013. 14(4): p. 335-45.
- Dalton, J.T., et al., The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle, 2011. 2(3): p. 153-161.
- Hoffmann, D.B., et al., Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis. Journal of Bone and Mineral Metabolism, 2019. 37(2): p. 243-255.
- Komrakova, M., et al., The Selective Androgen Receptor Modulator Ostarine Improves Bone Healing in Ovariectomized Rats. Calcified Tissue International, 2020. 106(2): p. 147-157.
- Yuan, Y., et al., A Phase II Clinical Trial of Pembrolizumab and Enobosarm in Patients with Androgen Receptor‐Positive Metastatic Triple‐Negative Breast Cancer. The Oncologist, 2020. 26(2): p. 99-e217.
Certificate of Analysis (COA)
High Performance Liquid Chromatography (HPLC)
What is Mk-2866?
MK-2866, also known as Ostarine, is a selective androgen receptor modulator (SARM). It has drawn interest due to potential anabolic and tissue-specific actions, which make it an interesting research topic. MK-2866 targets skeletal muscle and bone tissue by attaching to androgen receptors in the body. It is thought to encourage muscular growth, improve strength, and maybe help with injury healing. MK-2866 has been researched for its possible use in treating diseases like osteoporosis, muscular wasting, and hormone replacement treatment. It is crucial to remember that MK-2866 is only meant for research at this time and has not yet received approval for use in humans.
Selective androgen receptor modulator (SARM) MK-2866, also referred to as Ostarine, has drawn a lot of interest from researchers. Its potential anabolic effects, tissue selectivity, and therapeutic implications in a variety of illnesses have all been studied.
Mechanism of Action:
MK-2866 primarily targets skeletal muscle and bone tissue by binding to androgen receptors in the body. It has tissue-selective anabolic actions, which reduce the possibility of adverse effects on other organs, in contrast to typical anabolic steroids.
Muscle Building and Performance Enhancement:
MK-2866 study has focused on the substance's role in fostering muscle growth and improving athletic performance. MK-2866 can increase muscle mass, strengthen muscles, and improve athletic performance, according to studies. It is thought to promote protein synthesis, resulting in muscular growth and maybe assisting in the recovery from disorders that cause muscle wasting.
Treatment of Muscle Wasting and Sarcopenia:
MK-2866 study has examined its therapeutic potential in diseases like sarcopenia and cancer cachexia, which are linked to muscle wasting. MK-2866 may be able to assist people with these illnesses maintain their strength and muscular mass, according to preliminary studies that have produced encouraging findings. To establish its efficacy and safety for clinical application, more research is required.
Bone Health and Osteoporosis:
Studies have also looked into how MK-2866 affects osteoporosis and bone health. Research suggests that MK-2866 may improve bone strength and mineral density, potentially providing a unique method for treating osteoporosis and enhancing bone health.
Hormone Replacement Therapy:
MK-2866 has been studied for its ability to treat androgen deficit in patients by replacing their missing hormones. MK-2866 has been demonstrated in studies to help hypogonadal males gain lean body mass and improve muscle strength. It is significant to emphasize that additional study is required to completely confirm hormone replacement therapy's safety, efficacy, and long-term effects.
Safety and Side Effects:
MK-2866 research has also concentrated on assessing the drug's safety profile and any side effects. Despite being usually well tolerated, studies have noted moderate negative effects such testosterone suppression, alterations to lipid profiles, and potential cardiovascular risks. To completely comprehend its possible hazards and long-term safety, more study is required.
Where to Buy MK-2866
If you want to buy MK-2866 online you can avail it at Pinnacle Peptides. We have been one of the trusted online sources in the market, as only high quality products are made available at our website at unbeatable prices. Pinnacle Peptides understands your requirements and hence have gathered some of the largest lab supplies you can find at the online store. If you order bulk items you will also get great discounts. If you are a scientist looking to purchase MK-2866, you have come to the right place. Pinnacle Peptides only stocks the most relevant products that are highly in demand from researchers. Buying bulk quantities of MK-2886 can be beneficial as exclusive discounts can be availed. However, MK-2866 for sale here is only available for research purpose, not for human consumption.
The products we offer are intended for laboratory research use only. In purchasing any of these items, the customer acknowledges that there are risks involved with consumption or distribution of these products. These chemicals are NOT intended to use as food additives, drugs, cosmetics, household chemicals or other inappropriate applications. The listing of a material on this site does not constitute a license to its use in infringement of any patent. All of the products will be handled only by qualified and properly trained professionals. All customers represent and warrant that through their own review and study that they are fully aware and knowledgeable about the following: Government regulations regarding the use of and exposure to all products. The health and safety hazards associated with the handling of the products they purchase. The necessity of adequately warning of the health and safety hazards associated with any products. Pinnacle Peptides and pinnaclepeptides.com reserves the right to limit and/or deny sales of products to any unqualified individuals if we have reason to believe that misuse will occur.